Yipinhong Pharmaceutical Co Ltd
SZSE:300723

Watchlist Manager
Yipinhong Pharmaceutical Co Ltd Logo
Yipinhong Pharmaceutical Co Ltd
SZSE:300723
Watchlist
Price: 16.47 CNY -6.74% Market Closed
Market Cap: 7.4B CNY
Have any thoughts about
Yipinhong Pharmaceutical Co Ltd?
Write Note

Yipinhong Pharmaceutical Co Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Yipinhong Pharmaceutical Co Ltd
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Yipinhong Pharmaceutical Co Ltd
SZSE:300723
Cost of Revenue
-ÂĄ558.6m
CAGR 3-Years
-18%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cost of Revenue
-ÂĄ1B
CAGR 3-Years
-9%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Cost of Revenue
-ÂĄ5.9B
CAGR 3-Years
-15%
CAGR 5-Years
-14%
CAGR 10-Years
-24%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cost of Revenue
-ÂĄ3.9B
CAGR 3-Years
0%
CAGR 5-Years
-5%
CAGR 10-Years
-11%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cost of Revenue
-ÂĄ28.7B
CAGR 3-Years
-3%
CAGR 5-Years
-8%
CAGR 10-Years
-9%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cost of Revenue
-ÂĄ242.3m
CAGR 3-Years
-6%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Yipinhong Pharmaceutical Co Ltd
Glance View

Market Cap
7.5B CNY
Industry
Pharmaceuticals

ApicHope Pharmaceutical Co., Ltd. engages in the research and development, production and sale of chemical medicine and traditional Chinese medicine products. The company is headquartered in Guangzhou, Guangdong and currently employs 1,079 full-time employees. The company went IPO on 2017-11-16. The firm has two types of products which are children's drugs and chronic disease drugs. The children's drugs are used for the treatment of colds, digestive anorexia, viral infections, children's eczema and other diseases, including clindamycin palmitate dispersible tablets and clindamycin palmitate granules. The chronic disease drugs include hepatocyte growth-promoting hormone for injection, aceglutamine for injection and adenosine cyclophosphate for injection, which are used for the treatment of severe viral hepatitis and cardiovascular and cerebrovascular diseases. The firm is also engaged in selling drugs for agents.

Intrinsic Value
17.61 CNY
Undervaluation 6%
Intrinsic Value
Price

See Also

What is Yipinhong Pharmaceutical Co Ltd's Cost of Revenue?
Cost of Revenue
-558.6m CNY

Based on the financial report for Jun 30, 2024, Yipinhong Pharmaceutical Co Ltd's Cost of Revenue amounts to -558.6m CNY.

What is Yipinhong Pharmaceutical Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-12%

Over the last year, the Cost of Revenue growth was -31%. The average annual Cost of Revenue growth rates for Yipinhong Pharmaceutical Co Ltd have been -18% over the past three years , -12% over the past five years .

Back to Top